In this cross-sectional study of adults hospitalized with respiratory syncytial virus (RSV) before the 2023 introduction of RSV vaccines, RSV was associated with substantial burden of hospitalizations ...

S4V2 will be tested for safety and preliminary efficacy in approximately 120 healthy Shigella -naïve participants aged 18 to 50 years at three sites in the United States. The study, sponsored and ...

The newest case is the fifth to bring similar allegations against Moderna in the same court, with three others, all filed Nov ...

Hope is on the horizon for needle-phobic patients as Griffith University researchers have created a new influenza vaccine ...

The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...

The holidays are fast approaching along with cooler weather and various respiratory illnesses. Here's when to get your ...

Revenue: Revenue for the three months ended September 30, 2024, increased to approximately $1,958,000 compared to $397,000 ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

As cold and flu season ramps up, the most vulnerable among us need extra protection. Infants are among the most susceptible ...

“RSV is now circulating at higher levels ... For clinical trials, including vaccine trials, the vaccine manufacturers and ...

Image by Arek Socha from Pixabay November 12, 2024 - By Lorna Fernandes - As fall arrives, so does respiratory syncytial ...

Because the RSV vaccine was ultimately approved for administration during a narrower gestational age window than was ...